GPR52 and prostate carcinoma: The study found that GPR52 downregulation involved in aggressive prostate carcinoma recurrence with MTIE (Demidenko et al. 2017); C12orf40 acted as prognostic biomarkers for kidney renal clear cell carcinoma (Yang et al. 2020).